S&P BSE BasicMat News and Updates

Name: Latest research reports of Nuvoco Vistas Corporation Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Nuvoco Vistas Corporation Ltd.
Rating: 4
Author: Prabhudas Lilladhar

Keep track of all breaking news on S&P BSE BasicMat from all sources in a single place.

Load latest

Gravita India Ltd.

06 May 2025

1850.00

-1.63%

Gravita India Shares May Rise 38%, Says ICICI Securities As It Maintains 'Buy' Post Q4 Earnings

NDTV Profit

Adjusting for the recently concluded QIP, ICICI Securities' revises target price to Rs 2,670 (earlier Rs 3,250 and maintain 'Buy' rating.

Gravita India Ltd.'s price crossed below 50Day SMA today

Ambuja Cements Ltd.

06 May 2025

557.05

0.34%

Ambuja, Shree Cement Among Nomura's Top Picks As Cement Prices Rise In East, South

NDTV Profit

Nomura sees volume, pricing tailwinds as dealers report hikes of up to Rs 12 per bag.

Ambuja Cements Ltd. is trading above all available SMAs

Nuvoco Vistas Corporation Ltd.

06 May 2025

354.20

-2.28%

Nuvoco Vistas Corporation (NUVOCO IN) Q4FY25 Result Update ...

Accumulate: Nuvoco Vistas Corporation ...

Target

Prabhudas Lilladhar

Nuvoco plans to raise Rs6bn of long-term debt in own books and rest Rs12bn through bridge loans for Vadraj upfront payment. Post the deal, it plans to raise Rs12bn through the CCPS and CCD route to keep leverage at lower side. Nuvoco Vistas (NUVOCO) reported a robust operating performance in Q4FY25, driven by 6.6% YoY volume growth and a strong uptick in cement pricing in key markets, supported by increased government spending. Pure cement NSR rose 5% QoQ, aided by price increases in the eastern markets during Q4FY25. As per mgmt., April prices are higher by Rs810/bag, which is...

Nuvoco Vistas Corpor.. has an average target of 367.00 from 3 brokers.

Atul Ltd.

06 May 2025

7438.00

0.81%

Capacity in action: Utilization gains to drive earnings; Buy

Buy: Atul Ltd.

Anand Rathi

Atul invested ~Rs20bn over the last three years in setting up capacity (capex matching the cumulative investment over the last decade). In its analyst meet, management highlighted unrealized sales potential of over Rs25bn from recently concluded capex (~Rs17bn) and from previously unutilized capacity (~Rs8bn).

Atul Ltd. has gained 30.56% in the last 3 Months

Tatva Chintan Pharma Chem Ltd.

06 May 2025

968.95

3.88%

TATVA remain hopeful for strong recovery in FY26

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

Tatva Chintan Pharma Chem’s (TATVA) performance showed signs of improvement in Q4FY25 on the revenue front, but lower gross profit marred profit recovery. TATVA is hopeful of a sharp recovery in FY26, as new products commercialise in PASC and SDA volume recovers.

Tatva Chintan Pharma Chem Ltd. has gained 36.37% in the last 3 Months

Gravita India Ltd.

06 May 2025

1850.00

-1.63%

Good showing; sticking to growth plan

Buy: Gravita India Ltd.

Target

ICICI Securities Limited

Gravita India’s (GRAV) performance was in line with our estimates. EBITDA (including hedging gains) was up 22% YoY at INR 1.06bn. EBITDA margin (adj.) was up 20bps YoY (30bps QoQ) at 10.3%. Lead sales volume rose 12.3% YoY at 45.6kt.

Gravita India Ltd.'s price crossed below 50Day SMA today

Nuvoco Vistas Corporation Ltd.

06 May 2025

354.20

-2.28%

Debt cloud lingers, but margins shine through

Hold: Nuvoco Vistas Corporation ...

Recommendation Target

ICICI Securities Limited

Q4FY25 turned out to be a dream quarter for Nuvoco Vistas Corp (Nuvoco) with an all-time high EBITDA (up 12% YoY), being 24% ahead of our estimate (driven by beat across realisation and cost); and net debt retreated further to INR 36.4bn (down ~INR 4bn YoY).

Nuvoco Vistas Corporation Ltd. is trading above all available SMAs

Gravita India Ltd.

06 May 2025

1850.00

-1.63%

Result Update:Gravita India

Buy: Gravita India Ltd.

Target

Axis Direct

We maintain our BUY recommendation on the stock.

Number of MF schemes increased from 8 to 14 in Mar 2025 qtr.

Epigral Ltd.

06 May 2025

1833.70

2.95%

In-line quarter; volume growth guidance maintained

Buy: Epigral Ltd.

Target

Emkay

Epigral posted in-line results, with revenue/EBITDA/PAT up 20%/12%/12% YoY. This was largely led by improvement in ECUs in the caustic soda business and higher realizations for ECH (because of ADD), volume growth in the derivatives and specialty segment (CPVC, ECH).